Introduction
Healthcare in the 21st century is challenged by an increasing number of people experiencing noncommunicable chronic diseases. Cardiovascular disease (CVD) affects most men beyond the age of 55 years and women beyond 65 years of age. 1 Consequently, CVD is generally regarded an ageing disorder. However, it has long been known that fatty streaks and subsequent plaque formation already starts at a very young age, and the pace of progression is related to plasma low-density lipoprotein cholesterol (LDL-C) levels concentration. 2 To curtail this threat, early prevention seems the preferred approach to curb this exponential increase in avoidable chronic diseases. 3, 4 From this perspective, the early identification of modifiable risk factors, especially dyslipidemia, is key to effective prevention and management of CVD. 2, 5 Cohort studies can provide insight in what is needed to promote ''healthy ageing'' and find solutions for early identification and intervention of individuals at increased CVD risk. The Lifelines cohort study, initiated in 2006, is the largest ongoing prospective observational European population study to date. 6 Study participants, 152,180 adult inhabitants of the northern part of the Netherlands, were recruited by their primary care physicians, through family members or by registering at the Lifelines Website (www. lifelines.nl). The total duration of follow-up will be 30 years, the first 5-year follow-up visit is in process, the next 10-year follow-up visit is being planned. Data consist of self-reported/validated questionnaires, routine clinical biochemistry, physical examination, biobanking of biomaterials including blood, urine, and feces and genome-wide genotyping. Thereby, the Lifelines study can provide insight into the prevalence and incidence of multifactorial diseases and their risk factors, including lipids. Based on the concepts of modifiers and the three-generation design, this study may provide better understanding of the causes and prognosis of dyslipidemia over a lifetime. This may ultimately result in optimal tailored treatment of, for example, hypercholesterolemia, overriding standard preventive strategies.
Identifying dyslipidemia requires knowledge of the normal distribution of blood lipids in the population. Reference values for total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides have been collected in numerous studies and cohorts. However, contemporary and comprehensive percentile-based reference values are surprisingly missing. Apart from the broad variation of these values in different geographical regions, 7 there are also time-dependent changes reflecting modifications in age, lifestyle, and pharmaceutical interventions. 8, 9 This article aims to provide baseline information and facilitate future research, by providing age-and genderbased reference values for lipid levels. These lipid reference values are indispensable for comparison with populations from different regions or different genetic background, as well as monitoring prospective changes. Importantly, they can also serve the early identification of individuals with, for example, familial hypercholesterolemia, a common but underdiagnosed and undertreated genetic disease. 2 
Methods

Participants
Lifelines is a large population-based prospective cohort study conducted in the north of the Netherlands. Participants of almost exclusively Caucasian descent were included between 2006 and 2013. The study protocol was approved by the medical ethics committee of the University Medical Center Groningen, and all participants provided written informed consent. The design and rationale of the study are described elsewhere. 6 In short, general practitioners asked their patients, between the age of 25 and 50 years, if they were willing to participate. After a positive response, family members from all ages (partner, parents, parents-in-law, and children) were also invited to participate. In addition, individuals aged $18 years could become a participant through self-registration. These individuals were also asked to invite family members.
At baseline, all participants filled out questionnaires and underwent a comprehensive physical examination. The questionnaires covered health topics, psychosocial parameters, information on lifestyle, and medication use (including lipid-lowering drugs). Physical examination included anthropometry, blood pressure measurement, pulmonary function tests, echocardiogram, and a neuropsychiatric interview. Fasting blood was drawn from all participants for clinical chemistry measurements including plasma lipids.
Exclusion criteria
The data of children (aged ,18 years) have not yet been released and could therefore not be included. Participants with a history of CVD at baseline, defined as myocardial infarction, coronary surgery (balloon angioplasty or bypass surgery) or stroke, were excluded. Transient ischemic attack and peripheral vascular disease could not be accounted for because these clinical features could not be adequately scored with the questionnaires used. In addition, participants reporting lipid-lowering drug use (ie, statins, fibrates, or ezetimibe) at baseline, and those with nonfasting blood tests at baseline were excluded from this analysis.
Cholesterol measurements
Venous blood samples were collected following a standard protocol, after an overnight fast. Plasma from heparinized tubes was used for clinical chemistry. Lipid measurements were performed using Roche Modular P automated analyzer (Mannheim, Germany). Total cholesterol and LDL-C were measured with a direct enzymatic colorimetric assay using cholesterol esterase and cholesterol oxidase. Total cholesterol was standardized against isotope dilution-mass spectrometry and LDL-C was standardized against the beta quantification method. HDL-C was measured with a third-generation direct quantitative enzymatic colorimetric assay using polyethylene glycolcholesterol esterase and polyethylene glycol-cholesterol oxidase and standardized against the CDC reference method. 10 Triglycerides were measured using an assay based on glycerol phosphate oxidase-peroxidase aminophenazone and standardized against isotope dilution-mass spectrometry. LDL-C was also calculated with the Friedewald formula (total cholesterol 2 HDL-C -[triglyceride/ 5.0]). When using this formula, 1387 individuals with triglyceride levels .400 mg/dL were excluded. 11 Apolipoprotein (Apo) B and ApoA-I were only measured in the first 6038 individuals that were enrolled. Because of the design of the Lifelines study, these 6038 individuals are between 25 and 50 years of age. Therefore, the data of Apo B and Apo A-I are not presented in this study.
Statistical analysis
All analyses were carried out using IBM SPSS Statistics, version 22.0 (IBM Corp, Armonk, NY). Baseline characteristics of normally distributed variables were reported as mean and standard deviation. Student's t-test was used to compare the means of two groups. Not normally distributed parameters were reported as median and interquartile range. Mann-Whitney U test was used to compare the medians between males and females.
Plasma lipid levels were analyzed for men and women separately at baseline. The 
Results
Population characteristics
Of the 152,180 participants, 18,640 (12%) were excluded because of CVD, use of lipid-lowering drugs (statins, fibrates, or ezetimibe), nonfasting blood tests, or missing lipid data (Fig 1) . 
Age, gender, and LDL-C levels
At 20 years of age, men presented with significantly lower LDL-C levels compared with women (median: 85 vs 97 mg/dL; 95 th percentile: 139 vs 151 mg/dL; P , .001). It is clear that in both genders LDL-C increases with age, but the dynamics were strongly gender specific: in men, LDL-C increased markedly from adolescence and peaked at 45 to 49 years of age (median: 139 mg/dL; 95 th percentile: 197 mg/dL). At higher ages LDL-C levels show a gradual decrease. This is illustrated by men $ 80 years, whose LDL-C levels were significantly lower than those aged 60 to 64 years (median: 131 vs 143 mg/dL; 95 th percentile: 183 vs 197 mg/dL; P , .001).
In women, by contrast, median LDL-C was stable until their mid-30s, after, which LDL-C increased to a maximum at 55 to 59 years (median: 143 mg/dL; 95 th percentile: 205 mg/dL). There was no clear decline at higher ages in women as was observed in men. Another interesting finding is the enormous distribution of LDL-C levels in this apparently healthy general population. For example, in males, aged 35 to 39 years, 90% of the LDL-C levels are within 81 and 186 mg/dL.
While the current data were generated with direct lipid quantification methods, LDL-C is typically calculated using the Friedewald formula.
11 Calculated LDL-C in our study provides lower values compared with direct LDL-C quantification for both genders ( Supplementary  Fig. 1 ). The median Friedewald LDL-C was 7.0 mg/dL lower in men and 6.0 mg/dL lower in women. With increasing triglyceride levels, a greater absolute difference was noted.
Age, gender, and HDL-C levels
In the different age groups of men, median HDL-C fluctuated between 46 and 54 mg/dL. In all age groups, apart from 35 to 39 years, the 5 th percentile was 35 mg/dL. HDL-C did not significantly increase in older men. In women, median HDL-C increased from 54 mg/dL at young age (,20 years) to 66 mg/dL at the age of 50 years. Above the age of 50 years, no changes in HDL-C levels were noticed. The 5 th percentile was 39 mg/dL in women aged ,45 years and 43 mg/dL in those aged $ 45 years.
Age, gender, and triglyceride levels
Of all lipids, the relation between triglycerides and age showed the most pronounced differences between men and women. In men, triglyceride levels strongly increased from young age (median: 71 mg/dL; 95 th percentile: 153 mg/dL) until 40 to 44 years of age (median: 106 mg/dL; 95 th percentile: 289 mg/dL), thereafter, triglyceride levels dropped rapidly with advancing age. Interestingly, this increase was most prominent at the 75 th , 90 th , and 95 th percentiles and almost absent at the 5 th and 10 th percentiles. In sharp contrast with the observations in men, triglyceride levels in women were relatively stable and median levels fluctuate between 68 and 77 mg/dL from 20 to 50 years of age. After 50 years of age, triglyceride levels increased moderately.
Reference values
Supplementary Tables 2 and 3 provide the (reference) values of all blood lipids (including total cholesterol and TC/HDL-C ratio) for men and women at five-year age intervals. These reference values are also available at www. my-cholesterol.care/. Supplementary Table 4 shows the effect of BMI on the age-and gender-specific 5 th , 50 th , and 95 th percentiles.
Discussion
In this article, we describe the distribution of lipid and lipoprotein levels in the general adult population of the Netherlands. We anticipate that this large and unique cohort will provide the scientific and clinical community valuable new insights in the (near) future. Unique are the long and frequent follow-up visits; every 1.5 years participants fill in questionnaires, and every five years participants visit the Lifelines research site for a physical examination and biomaterial collection. Participants will be followed for at least 30 years. More than 6,000,000 samples of biomaterials will be stored in the Lifelines biobank. The innovative and unique three-generation design opens an exclusive opportunity for the study of the environmental as well as the genetic effects on lipid levels and CVD risk.
The presented lipid data from the Lifelines study provide several important findings:
(1) The analysis shows prominent gender-and age-related differences in all main plasma lipids and lipoproteins. Our analysis reveals the need to correct for age and gender when evaluating a lipid profile. Although these observations are cross-sectional, and conclusions on the true changes in lipids over time are hazardous, it is interesting to note that our cross-sectional data are comparable to the cross-sectional data from the Lipid Research Clinics (LRC) Prevalence study (see in the following). (2) High LDL-C is common in the northern provinces of the Netherlands and the prevalence in young individuals is higher than anticipated. Many (young) individuals suffer from unknown hypercholesterolemia. Based on these outcomes, strategies to improve these modifiable risk factors need to be formulated at both the individual as well as population level. (3) The data presented in this study, and the accompanying appendices, can be used as reference baseline values for the standard lipoprotein parameters: total cholesterol, LDL-C, HDL-C, and triglycerides. This will facilitate the evaluation of (population) interventions in the future and can be used as a comparator for other prospective or retrospective lipid profile analyses in different geographic regions. For use in clinical practice, an interactive Website is available at www. my-cholesterol.care/.
Reference values in clinical practice
We value early identification of individuals with increased LDL-C of utmost importance. Generating solid scientific evidence that early (lifestyle and, in high-risk individuals, pharmaceutical) intervention in primary care is beneficial, proves to be extremely difficult. Attempts to provide such evidence with one of the largest prospective cohort studies, the Copenhagen study group (personal communication with B.G. Nordestgaard) have failed because of lack of power. However, it is in our opinion a matter of common sense to reduce the burden of unhealthy lifestyle behaviors early in life, especially in individuals with LDL-C above the 95 th percentile for age and gender. It was recently shown that counseling for a healthy lifestyle for five year led to lifelong (40 year) benefits.
14 Our data can be used to show individuals why they must act to attenuate the potential increase of their high LDL-C levels.
Using the cut-off levels of the 1 st and 99 th percentiles, extreme lipid phenotypes can be identified, facilitating early identification of hypercholesterolemia and hypocholesterolemia in patients (and their families at increased CVD risk). Further examination of these individuals would allow for in-depth analysis of the underlying causes of these severe dyslipidemias, generating opportunities to unravel (novel) pathways that are related to hypocholesterolemia and hypercholesterolemia. Apart from LDL-C, our data could also be of use in the identification of individuals with extremely low HDL-C, which is a useful marker for poor prognosis. 15 Our study shows an impressive increase in LDL-C with ageing. When using fixed LDL-C cut-off values, young individuals with age-and gender-corrected very high LDL-C are in peril of not being identified as having an increased CVD risk. Why appropriate identification of these young individuals is so important was shown in the Atherosclerosis Risk in Communities study. 16 AfroAmerican individuals with a proprotein convertase subtilisin/kexin type 9 (PCSK9) loss of function mutation presented with a 28% reduction in LDL-C, this translated into an impressive 88% reduction of CVD risk. Caucasian carriers of another PCSK9 loss of function mutation presented with a reduction of only 15% in LDL-C levels, but a striking 47% reduction in CVD risk. An explanation for these remarkable observations is that individuals with a loss of function mutations in PCSK9 benefit from lifelong lower LDL-C levels. 
Comparing the Lifelines to other cohort studies
To our knowledge, currently used lipid reference values are largely based on the cross-sectional LRC Prevalence study that was carried out in the 1970s.
12,13 Figure 4 shows the comparison of total cholesterol, LDL-C, and triglycerides of these studies. In men, only very small differences in total cholesterol between the studies were observed. Women in Lifelines, however, presented with approximately 6.0 mg/dL lower total cholesterol levels between th , 90 th and 95 th age-specific percentile curves for total cholesterol, LDL-C, and calculated LDL-C (using Friedewald formula) in men (left) and women (right). LDL-C, low-density lipoprotein cholesterol. the ages of 30 to 55 years. A similar pattern is also present in distribution of LDL-C. Triglycerides seem to be lower in the Lifelines study in all percentiles, however, the patterns are comparable.
The similarity of the LDL-C distribution among both studies is surprising in the context of the National Health and Nutrition Examination Surveys (NHANES) showing nation-wide improvements in lipid levels in the United States over the past 60 years. [17] [18] [19] This phenomenon may also apply for the situation in the north of the Netherlands. We can speculate that total cholesterol levels may have been higher in our study population in the 1970s. Alternatively, the Lifelines population may currently still reflect the situation of the 1970s in the United States. We have recently shown that the overall adherence to guidelines is quite poor, 20 and this could also apply to improved lifestyle changes. In this regard, still 21% of the population smokes tobacco. Another point that may merit attention is that we have excluded individuals reporting lipid-lowering medication. The use of lipidlowering drugs become more widely accepted after the Prevalence study, and lipid-lowering drug use certainly have a huge effect on total cholesterol distribution curves. Difference in the cholesterol analysis methods might also explain the higher total cholesterol levels observed in Lifelines. However, only in middle-aged females, total cholesterol levels were lower. As this effect is gender specific, it is unlikely to be related to differences in methods of measurements only. This is not in-line with an overall technical issue underlying our observations. It should also be noted that not all population studies show a decrease in cholesterol levels over time in all age groups. For example, the Minnesota Heart Survey showed that between 1980 and 2002, no changes in lipid levels were present in individuals aged between 25 and 44 years. 21 It is likely that this also applies to the Lifelines population.
A direct comparison of mean calculated LDL-C levels between NHANES 22 and Lifelines population shows that calculated LDL-C levels are similar across all age groups, apart from 30 to 39 years, where LDL-C appears lower in the Lifelines cohort (see Supplementary Table 5) . LDL-C means of the complete Lifelines cohort (including individuals reporting CVD and lipid-lowering drugs) are more comparable to the NHANES study in comparison to Lifelines individuals without CVD and lipid-lowering drug use. The mean LDL-C levels from Question diagnostics 23 are substantially lower across all age groups (see Supplementary Table 5 ). This is probably due to methodology: the latter population is a patient-based sample. Figure 4 Comparing levels of total cholesterol, LDL-C, and triglycerides as measured in the LRC Prevalence study, the AHA special report, and the Lifelines study. The 5 th , 25 th , 50 th , 75 th , and 95 th age-specific percentile curves for total cholesterol, LDL-C, and triglycerides are presented for the LRC Prevalence study (solid line), 12 the AHA special report (dotted line), 13 and Lifelines study (interrupted line), in men and women. LDL-C levels from Prevalence study and AHA special report were similar. LDL-C, low-density lipoprotein cholesterol; LRC, Lipid Research Clinics; AHA, American Heart Association.
Direct vs calculated measurement of LDL-C
In the Lifelines study, the median Friedewald LDL-C was overall 7.0 mg/dL lower in men, and 6.0 mg/dL in women, compared with direct LDL-C measurements. Many studies have investigated the difference between direct measurement and calculated LDL-C. It was shown in 27,331 healthy women that direct measurement was also lower compared with the Friedewald equation. However, both methods showed similar association of LDL-C with CVD. 24 In a large American study, it was also shown that Friedewald-estimated LDL-C levels were lower than the direct measurement, especially at low LDL-C levels (,70 mg/dL) and high triglyceride levels. 25 For an extensive and fair comparison, the measurements should be compared with ultracentrifugation, the golden standard. This process is however not suited for large-scale routine use and therefore not available in our cohort. In clinical practice, however, both the direct measurement as the calculated LDL-C are often used. This analysis reemphasizes the need to answer the question whether the Friedewald or direct measurement should be used in treatment decisions.
Strengths and weaknesses
The large sample size of participants and the comprehensive data that are collected makes this a unique cohort primed for translational research analysis. In Lifelines, approximately one-third of the participants' family members participated, providing a unique opportunity to analyze genetic traits. The Lifelines cohort is a large representative sample of the general population of the north of the Netherlands. 26 Because of multiple recruitment strategies including general practitioners' patient files, family referral, and self-registration, a representative study sample was achieved. Lifelines is broadly representative on lifestyle, diseases, and general health. The risk of selection bias is low. However, middle-aged men and women are overrepresented. Because we investigated the effect of age on gender on lipid parameters, this could not have influenced our results.
A limitation is that the data set used is cross-sectional but so far, references values were based on the likewise crosssectional (very similar) data of the LRC Prevalence study. Naturally, prospective data will become available (earliest autumn 2017). Generalizability of this study is limited because participating was and is voluntary, so that the study sample was self-selected. Another unfortunate limitation is that the participants of Lifelines are almost exclusively of Caucasian descent. Thus, our reference ranges will not be applicable to other ethnicities: more than 98% of the Lifelines cohort is of Caucasian Northern/West European descent.
Conclusions
Our data show prominent differences in lipid profiles between gender and age. This study provides tools, that is, gender-and age-specific reference values of contemporary blood lipid levels (available at www.my-cholesterol.care/) that may be used to identify young individuals with atherogenic dyslipidemia, and therefore increased risk of CVD.
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